Background and Objectives: In contrast with sporadic colorectal cancer liver metastases (CRLM), inflammatory bowel disease (IBD)-related CRLM have not been studied to date. Methods: Patients who underwent resection for IBD-related and sporadic CRLM from 2000 to 2015 were identified from an international registry and matched for pertinent prognostic variables. Overall survival (OS) and recurrence-free survival (RFS) were subsequently assessed. Results: Twenty-eight patients had IBD-related CRLM. Synchronous extrahepatic disease was more common in IBD-related CRLM patients than patients with sporadic CRLM (28.6% vs 8.3%; P < 0.001), most commonly located in the lungs. In multivariable analysis, IBD did not have a significant influence on OS (P = 0.835), and had a hazard ratio (HR) close to 1 (HR, 0.95; 95% confidence interval [CI], 0.57-1.57). IBD was also not associated with inferior RFS (HR, 1.07; 95%CI, 0.68-1.68; P = 0.780). Among patients with IBD-related CRLM, 9(50%) had isolated intrahepatic recurrence and 8(44.4%) isolated extrahepatic recurrence, while only 1(5.6%) developed combined recurrence. Of those who experienced recurrence after resection of IBD-related CRLM, 10 had their recurrence treated with curative intent. Conclusions: Patients with IBD-related CRLM had similar survival compared with patients with sporadic CRLM, even though they more often present with extrahepatic disease. In addition, patients with IBD-related CRLM may experience patterns of recurrence different from patients with sporadic CRLM.

colorectal liver metastases (CRLM), inflammatory bowel disease (IBD), overall survival (OS), recurrence
dx.doi.org/10.1002/jso.25251, hdl.handle.net/1765/110614
Journal of Surgical Oncology
Department of Surgery

Margonis, G.A. (Georgios Antonios), Büttner, S, Andreatos, N. (Nikolaos), Wagner, D. (Doris), Sasaki, K. (Kazunari), Galjart, B. (Boris), … Weiss, M. (2018). The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis. Journal of Surgical Oncology. doi:10.1002/jso.25251